Get the Stockscreener App
2.30
6.48%
0.14
After Hours:
2.30
C 4 Therapeutics Inc stock is traded at $2.30, with a volume of 1.60M.
It is up +6.48% in the last 24 hours and up +6.98% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.16
Open:
$2.15
24h Volume:
1.60M
Relative Volume:
1.08
Market Cap:
$222.90M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.8614
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
+21.69%
1M Performance:
+6.98%
6M Performance:
-11.88%
1Y Performance:
-23.59%
1-Day Range:
$2.12
$2.3299
1-Week Range:
$1.79
$2.3299
52-Week Range:
$1.085
$3.65
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.30 | 209.34M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.67 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Initiated | TD Cowen | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Brookline Capital Raises Price Target for C4 Therapeutics (CCCC) to $30 | CCCC Stock News - GuruFocus
CCCC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - Investing News Network
C4 Therapeutics doses first patient in phase 2 myeloma trial - Investing.com
C4 Therapeutics Doses First Patient in Phase 2 Trial of Cemsidomide Combination Therapy in Multiple Myeloma - marketscreener.com
Investor watch: C4 Therapeutics fireside chats in Boston and Miami - Stock Titan
New oral myeloma drug from C4 Therapeutics enters Phase 2 test - Stock Titan
What valuation multiples suggest for C4 Therapeutics Inc. stock2025 Price Action Summary & Short-Term High Return Strategies - mfd.ru
Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential - Yahoo Finance
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Bitget
C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Will C4 Therapeutics Inc. stock outperform tech sector in 2025Weekly Trend Recap & High Accuracy Investment Entry Signals - mfd.ru
Retail Trends: Is C4 Therapeutics Inc. stock a buy for dividend growth2025 Biggest Moves & Verified Technical Trade Signals - mfd.ru
Is C4 Therapeutics Inc. stock dividend yield sustainable2025 Retail Activity & Smart Allocation Stock Tips - mfd.ru
What is C4 Therapeutics Inc.’s valuation compared to sectorEarnings Risk Summary & Accurate Entry/Exit Alerts - mfd.ru
Can C4 Therapeutics Inc. reach all time highs this yearWeekly Gains Summary & Weekly Top Performers Watchlists - mfd.ru
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference - MarketBeat
Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Globe and Mail
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Institutional investors may adopt severe steps after C4 Therapeutics, Inc.'s (NASDAQ:CCCC) latest 11% drop adds to a year losses - simplywall.st
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New C4 Therapeutics hire receives options on 162,880 shares - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewswire Inc.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory - Finviz
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):